Oculis (NASDAQ:OCS) Hits New 12-Month High - What's Next?

Oculis Holding AG (NASDAQ:OCS - Get Free Report) shares hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $18.00 and last traded at $17.83, with a volume of 13043 shares changing hands. The stock had previously closed at $17.88.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a "buy" rating and set a $30.00 target price on shares of Oculis in a research report on Wednesday, October 23rd. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, Oculis has an average rating of "Buy" and a consensus target price of $29.20.

Oculis Stock Down 1.6 %

The firm has a market cap of $712.47 million, a price-to-earnings ratio of -9.15 and a beta of -0.18. The firm has a 50-day moving average price of $13.50 and a two-hundred day moving average price of $12.43. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.27 and a current ratio of 5.27.

Oculis (NASDAQ:OCS - Get Free Report) last released its quarterly earnings results on Tuesday, August 27th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.13). The firm had revenue of $0.27 million for the quarter, compared to analyst estimates of $0.28 million. Oculis had a negative return on equity of 61.33% and a negative net margin of 7,679.05%. On average, sell-side analysts forecast that Oculis Holding AG will post -2.19 earnings per share for the current year.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.